1-(5-1,3-dioxolan-2-yl-4,5-dihydro-isoxazol-3-yl)-4-methyl-piperidine | 1130365-72-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-(5-1,3-dioxolan-2-yl-4,5-dihydro-isoxazol-3-yl)-4-methyl-piperidine
• 英文别名: 5-(1,3-Dioxolan-2-yl)-3-(4-methylpiperidin-1-yl)-4,5-dihydro-1,2-oxazole
• CAS: 1130365-72-8
• 化学式: C₁₂H₂₀N₂O₃
• 分子量: 240.302
• InChiKey: GOCBLUZAROVNAN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  43.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-甲基哌啶 、 3-bromo-5-(1,3-dioxolan-2-yl)-4,5-dihydro-isoxazole 在 sodium carbonate 作用下， 以 正丁醇 为溶剂， 反应 6.0h， 以84%的产率得到1-(5-1,3-dioxolan-2-yl-4,5-dihydro-isoxazol-3-yl)-4-methyl-piperidine
  参考文献：
  名称：

  Synthesis of 3-Aminoisoxazoles via the Addition−Elimination of Amines on 3-Bromoisoxazolines

  摘要：

  A novel two-step procedure for the synthesis of 3-amino-5-substituted-isoxazoles Is described. In the presence of a base, readily available 3-bromoisoxazolines react with amines to afford 3-aminoisoxazolines. An oxidation protocol was developed for these heterocycles to provide 3-aminoisoxazoles in consistently high yield.

  DOI：

  10.1021/ol9000284

文献信息

• [EN] ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE<br/>[FR] ISOXAZOLINES EN TANT QU'INHIBITEURS DE L'HYDROLASE DES AMIDES D'ACIDES GRAS
  申请人：INFINITY PHARMACEUTICALS INC

  公开号：WO2010135360A1

  公开（公告）日：2010-11-25

  The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient. The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.

  本发明提供了式(I)的异噁唑啉FAAH抑制剂或其药用可接受形式，其中G、Ra、Rb、Rc和Rd中的每一个如本文所定义。本发明还提供了包括式(I)化合物或其药用可接受形式以及药用可接受赋形剂的药物组合物。本发明还提供了治疗FAAH介导疾病的方法，包括向需要的受试者施用式(I)化合物或其药用可接受形式的治疗有效量。
• ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE
  申请人：Behnke Mark L.

  公开号：US20110028482A1

  公开（公告）日：2011-02-03

  The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, R a , R b , R c , and R d are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient. The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.

  本发明提供了式(I)的异恶唑FAAH抑制剂或其药学上可接受的形式，其中G、Ra、Rb、Rc和Rd的定义如本文所述。本发明还提供了包括式(I)化合物或其药学上可接受的形式和药学上可接受的载体的制药组合物。本发明还提供了治疗FAAH介导的疾病的方法，包括向需要治疗的受体施用式(I)化合物或其药学上可接受的形式的治疗有效量。
• US8927551B2
  申请人：——

  公开号：US8927551B2

  公开（公告）日：2015-01-06
• Synthesis of 3-Aminoisoxazoles via the Addition−Elimination of Amines on 3-Bromoisoxazolines
  作者：Mélina Girardin、Pamela G. Alsabeh、Sophie Lauzon、Sarah J. Dolman、Stéphane G. Ouellet、Greg Hughes

  DOI：10.1021/ol9000284

  日期：2009.3.5

  A novel two-step procedure for the synthesis of 3-amino-5-substituted-isoxazoles Is described. In the presence of a base, readily available 3-bromoisoxazolines react with amines to afford 3-aminoisoxazolines. An oxidation protocol was developed for these heterocycles to provide 3-aminoisoxazoles in consistently high yield.